Gail Seiler testified at a 2024 U.S. Senate panel that a Texas hospital denied her food for 12 days, water for 7 days, and told her husband she was going to die after learning she was unvaccinated during a 2021 hospitalisation for COVID-19.
During their public testimony, Gail and Brad Seiler stated that when he arrived to remove her from the hospital, staff called the police—resulting in a six-hour standoff—before finally releasing her through a morgue service elevator while a nurse warned that she would be dead before reaching home.
Brad Seiler credited his wife’s full recovery to home-based care guided by a private physician using nebulised budesonide and ivermectin, stating that she was weaned off oxygen within 30 days, returned to work within 60 days, and is now healthy and active with her grandchildren.
Under the CARES Act, the federal government provided a 20% Medicare payment bonus for COVID-19 hospital admissions alongside higher standard reimbursements for intensive treatments like ventilation and remdesivir, though public health experts and billing audits confirm hospitals did not receive extra payouts for patient deaths.
Attorney Tom Renz testified that federal pandemic funding structures functionally incentivised the worst clinical outcomes over patient recovery, aligning with claims from families who argue these financial frameworks directly influenced hospital treatment decisions.
The Seilers’ testimony was presented at a September 2024 U.S. Senate roundtable hosted by Senator Ron Johnson, where they detailed how local political figures helped end the hospital standoff and credited Gail’s survival to alternative FLCCC medical protocols rather than standard NIH guidelines.
Every medication carries a risk of adverse effects because drugs interact with complex biological systems where a single compound can affect multiple organs or receptors simultaneously, which is why clinical regulators only approve a drug if its verified medical benefits outweigh these potential risks.
While many individuals choose to discontinue their prescriptions because the experienced side effects make them feel worse than their underlying illness, doing so without clinical supervision can lead to dangerous rebound symptoms, withdrawal syndromes, or unmanaged disease progression.
While every individual has the legal and personal right to make their own healthcare decisions, stopping a medication immediately because it makes you feel worse can be highly dangerous, as sudden discontinuation can trigger severe withdrawal, sudden rebound symptoms, or life-threatening medical emergencies.
For many types of medications—such as blood pressure pills, antidepressants, steroids, and heart medicines—the body rapidly adjusts its internal chemistry around the drug. Quitting “cold turkey” can shock the system, causing spikes in blood pressure, severe heart arrhythmias, or intense neurological setbacks that are far more harmful than the initial side effects. If a medication is making you feel ill, the safest approach is always to consult a doctor or pharmacist immediately so they can lower the dose, switch you to a safer alternative, or guide you through a controlled, gradual taper.
The global pharmaceutical industry generates nearly $1.9 trillion in annual revenue—with top companies like Johnson & Johnson and Roche leading the market—driven by high gross margins and exclusive 20-year patent protections on life-saving treatments, which executives argue funds expensive research and development despite significant corporate spending on marketing and administration.
The pharmaceutical industry is widely recognised as one of the most lucrative sectors in the global economy, consistently yielding net profit margins that outperform most other corporate industries due to its unique combination of legal monopolies and inelastic consumer demand.
While the pharmaceutical industry’s financial structure naturally incentivises recurring treatments for chronic illnesses over one-time solutions, the intense competition between rival corporations and the ability to charge premium prices for definitive cures mean that breakthrough treatments are still actively pursued.
